• Cardiff Oncology will hold a special stockholder meeting in San Diego on Oct. 22, 2026.
• Votes will be sought to raise authorized capital stock to 320,000,000 shares from 170,000,000.
• The proposal also lifts authorized common stock to 300,000,000 shares from 150,000,000; preferred stock authorization remains 20,000,000 shares.
• Stockholders will also vote on allowing an adjournment to seek additional support if votes are insufficient on the share increase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-368249), on August 26, 2026, and is solely responsible for the information contained therein.